BiotechTube

Placebo + Mirogabalin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Central Neuropathic Pain

Conditions

Central Neuropathic Pain

Trial Timeline

Mar 12, 2019 → Dec 28, 2020

NCT ID
NCT03901352

About Placebo + Mirogabalin

Placebo + Mirogabalin is a phase 3 stage product being developed by Daiichi Sankyo for Central Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03901352. Target conditions include Central Neuropathic Pain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03901352Phase 3Completed

Competing Products

20 competing products in Central Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
33
perampanelEisaiPhase 2
52
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
52
TirabrutinibOno PharmaceuticalPhase 1
33
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
52
pemetrexedEli LillyPhase 1
33
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
52
Leuprolide Acetate (LA)AbbViePhase 3
77
AcalabrutinibAstraZenecaPhase 2
52
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
77
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
41
TemozolomideMerckPhase 2
52
Verteporfin + ranibizumabNovartisPhase 1/2
41

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85